A Phase II Evaluation of DMAP [dacarbazine, mitomycin, doxorubicin, cisplatin] Plus GM-CSF [sargramostim] in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Dacarbazine; Doxorubicin; Mitomycin; Sargramostim
- Indications Uterine cancer
- Focus Therapeutic Use
- 11 Apr 2013 Biomarkers information updated
- 10 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 11 Sep 2005 New trial record.